TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
KR950000167A
(ko)
*
|
1993-06-24 |
1995-01-03 |
다께다 구니오 |
항-엔도테린 물질의 서방 제제
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
DE4342091A1
(de)
*
|
1993-12-09 |
1995-06-14 |
Asta Medica Ag |
Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
|
WO1996022786A1
(en)
*
|
1995-01-23 |
1996-08-01 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation and use
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
TW448055B
(en)
*
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
US6143037A
(en)
*
|
1996-06-12 |
2000-11-07 |
The Regents Of The University Of Michigan |
Compositions and methods for coating medical devices
|
US5932547A
(en)
*
|
1996-07-03 |
1999-08-03 |
Alza Corporation |
Non-aqueous polar aprotic peptide formulations
|
US5916582A
(en)
*
|
1996-07-03 |
1999-06-29 |
Alza Corporation |
Aqueous formulations of peptides
|
US5981489A
(en)
*
|
1996-07-18 |
1999-11-09 |
Alza Corporation |
Non-aqueous protic peptide formulations
|
ATE272394T1
(de)
|
1996-10-31 |
2004-08-15 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freisetzung
|
US5968895A
(en)
*
|
1996-12-11 |
1999-10-19 |
Praecis Pharmaceuticals, Inc. |
Pharmaceutical formulations for sustained drug delivery
|
US6126919A
(en)
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
US6030975A
(en)
*
|
1997-03-14 |
2000-02-29 |
Basf Aktiengesellschaft |
Carboxylic acid derivatives, their preparation and use in treating cancer
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
KR100584634B1
(ko)
*
|
1998-12-15 |
2006-05-30 |
다케다 야쿠힌 고교 가부시키가이샤 |
폴리머의 제조방법
|
JP2002537415A
(ja)
*
|
1999-02-19 |
2002-11-05 |
バイオサルフ アーゲー |
マイクロカプセルの製造のための生物分解性複合材料
|
US7358330B2
(en)
*
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
US20040023987A1
(en)
*
|
2000-06-14 |
2004-02-05 |
Yoshio Hata |
Sustained release compositions
|
CA2412899C
(en)
|
2000-07-05 |
2010-11-09 |
Takeda Chemical Industries, Ltd. |
Medicinal preparations for treating sex hormone-dependent diseases
|
ES2577389T3
(es)
*
|
2000-08-07 |
2016-07-14 |
Wako Pure Chemical Industries, Ltd. |
Polímero de ácido láctico y procedimiento para su producción
|
EP2062593A3
(de)
|
2000-12-01 |
2011-08-17 |
Takeda Pharmaceutical Company Limited |
Verfahren zur Herstellung einer Zubereitung mit bioaktiven Peptiden
|
CA2435415A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Microparticles of biodegradable polymer encapsulating a biologically active substance
|
WO2002058671A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Debio Recherche Pharmaceutique S.A. |
Burst free pharmaceutical microparticules
|
AU2002324447B2
(en)
|
2001-06-22 |
2006-06-29 |
Durect Corporation |
Zero-order prolonged release coaxial implants
|
TWI225416B
(en)
|
2001-06-29 |
2004-12-21 |
Takeda Chemical Industries Ltd |
Sustained-release composition and process for producing the same
|
US7282216B2
(en)
|
2001-11-12 |
2007-10-16 |
Alkermes Controlled Therapeutics, Inc. |
Biocompatible polymer blends and uses thereof
|
WO2003041739A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticaner agents
|
EP1476178A4
(de)
*
|
2002-02-14 |
2009-08-26 |
Bayer Pharmaceuticals Corp |
Formulierungsstrategien zur stabilisierung von peptiden in organischen lösungsmitteln und in getrockneten zuständen
|
US8299025B2
(en)
|
2005-02-03 |
2012-10-30 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006137953A1
(en)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
EP1716847B1
(de)
*
|
2005-04-28 |
2008-01-02 |
Nipro Corporation |
Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
|
KR101275660B1
(ko)
|
2005-05-23 |
2013-06-17 |
내츄럴 얼터너티브즈 인터내셔날, 인크. |
베타-알라닌의 지속적 방출을 위한 조성물 및 방법
|
EP1904525A4
(de)
*
|
2005-06-30 |
2009-10-21 |
Ipsen Pharma |
Glp-1 pharmazeutische zusammensetzungen
|
US7942867B2
(en)
*
|
2005-11-09 |
2011-05-17 |
The Invention Science Fund I, Llc |
Remotely controlled substance delivery device
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
PL2383271T3
(pl)
*
|
2006-03-13 |
2013-12-31 |
Kyorin Seiyaku Kk |
Aminochinolony jako inhibitory GSK-3
|
AU2007225139A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
CA2644784A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
US20090258028A1
(en)
*
|
2006-06-05 |
2009-10-15 |
Abbott Cardiovascular Systems Inc. |
Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
|
US8323676B2
(en)
*
|
2008-06-30 |
2012-12-04 |
Abbott Cardiovascular Systems Inc. |
Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
US8017237B2
(en)
|
2006-06-23 |
2011-09-13 |
Abbott Cardiovascular Systems, Inc. |
Nanoshells on polymers
|
KR101200728B1
(ko)
|
2006-08-09 |
2012-11-13 |
인타르시아 세라퓨틱스 인코포레이티드 |
삼투성 전달 시스템 및 피스톤 조립체
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
JP2010507585A
(ja)
|
2006-10-19 |
2010-03-11 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
置換インドール
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
CA2670976C
(en)
|
2006-11-30 |
2015-01-27 |
Atsushi Hasuoka |
Cyclic amine compound
|
TWI481424B
(zh)
*
|
2006-12-18 |
2015-04-21 |
Takeda Pharmaceutical |
緩釋性組成物及其製法
|
PT2144604E
(pt)
*
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
US20080220104A1
(en)
*
|
2007-03-08 |
2008-09-11 |
Cappello John V |
Compositions for producing satiety
|
PL2125698T3
(pl)
|
2007-03-15 |
2017-03-31 |
Auspex Pharmaceuticals, Inc. |
Deuterowana wenlafaksyna-d9
|
EP2139447A2
(de)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2170062A4
(de)
*
|
2007-07-12 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
Verfahren und zusammensetzungen zur behandlung von krebserkrankungen, tumoren und tumorvermittelten erkrankungen
|
ITSA20070024A1
(it)
*
|
2007-07-27 |
2009-01-28 |
Univ Degli Studi Salerno |
Processo continuo per la produzione di microsfere mediante liquidi espansi.
|
EP2203458B1
(de)
*
|
2007-09-11 |
2011-11-02 |
Kyorin Pharmaceutical Co., Ltd. |
Cyanoaminochinolone als gsk-3-inhibitoren
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
PT2268623E
(pt)
|
2008-03-17 |
2015-09-17 |
Ambit Biosciences Corp |
Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
US20100015220A1
(en)
*
|
2008-05-20 |
2010-01-21 |
Wetterau John R |
Niacin and nsaid combination therapy
|
US8765162B2
(en)
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
CA2729168A1
(en)
|
2008-07-02 |
2010-02-04 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
JP5744735B2
(ja)
*
|
2008-09-04 |
2015-07-08 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
非水性担体を用いた徐放性製剤
|
US8536114B2
(en)
|
2008-12-31 |
2013-09-17 |
Scynexis, Inc. |
Macrocycles
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
PT2401267E
(pt)
|
2009-02-27 |
2014-04-10 |
Ambit Biosciences Corp |
Derivados de quinazolina moduladores de quinase jak e sua utilização em métodos
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
CN102421784B
(zh)
*
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
RU2011143359A
(ru)
|
2009-03-27 |
2013-05-10 |
Патвэй Терапьютикс, Инк. |
Примидинил- и 1,3,5-триазинилбензимидазолсульфонамиды и их применение в терапии рака
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
CA2758985A1
(en)
|
2009-04-22 |
2010-10-28 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
MX2011011141A
(es)
|
2009-04-22 |
2012-02-13 |
Axikin Pharmaceuticals Inc |
Antagonistas ccr3 arisulfonamida.
|
NZ620074A
(en)
|
2009-04-22 |
2015-09-25 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
US8911766B2
(en)
*
|
2009-06-26 |
2014-12-16 |
Abbott Cardiovascular Systems Inc. |
Drug delivery compositions including nanoshells for triggered drug release
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
TW201105662A
(en)
|
2009-07-07 |
2011-02-16 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
PT2451435T
(pt)
|
2009-07-08 |
2018-01-15 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Composições farmacêuticas que contêm tiossulfato de sódio
|
WO2011009961A1
(en)
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
JP2013501068A
(ja)
|
2009-08-05 |
2013-01-10 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
JP2013514982A
(ja)
|
2009-12-18 |
2013-05-02 |
イデニク プハルマセウティカルス,インコーポレイテッド |
5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤
|
EP2515654A4
(de)
*
|
2009-12-23 |
2013-04-24 |
Map Pharmaceuticals Inc |
Neue ergolinanaloga
|
AU2010339460A1
(en)
|
2009-12-30 |
2012-07-19 |
Scynexis Inc. |
Cyclosporine analogues
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011097525A1
(en)
|
2010-02-05 |
2011-08-11 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
EP3202460B1
(de)
|
2010-02-11 |
2019-06-12 |
Celgene Corporation |
Arylmethoxyisoindolinderivate, zusammensetzungen damit und verfahren zur verwendung davon
|
DK2542542T3
(en)
|
2010-03-02 |
2015-07-20 |
Axikin Pharmaceuticals Inc |
ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
AR080770A1
(es)
|
2010-03-17 |
2012-05-09 |
Axikin Pharmaceuticals Inc |
Piperidinsulfonamidas moduladoras de la actividad de receptores xcc3, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de patologias respiratorias,tales como asma, entre otras.
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
JP6019015B2
(ja)
|
2010-06-01 |
2016-11-02 |
ビオトヘルイク, インコーポレイテッド |
6−シクロヘキシル−1−ヒドロキシ−4−メチル−2(1h)−ピリドンを使用する血液悪性疾患の治療方法
|
CN103038216A
(zh)
|
2010-06-01 |
2013-04-10 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
CN103108868B
(zh)
|
2010-06-07 |
2015-11-25 |
诺沃梅迪科斯有限公司 |
呋喃基化合物及其用途
|
US9295663B2
(en)
|
2010-07-14 |
2016-03-29 |
Abbott Cardiovascular Systems Inc. |
Drug coated balloon with in-situ formed drug containing microspheres
|
EP2595615A1
(de)
|
2010-07-19 |
2013-05-29 |
Summa Health System |
Vitamin c und chromfreies vitamin k sowie zusammensetzungen daraus zur behandlung von nfkb-induzierten leiden oder erkrankungen
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
ES2619850T3
(es)
|
2010-09-01 |
2017-06-27 |
Ambit Biosciences Corporation |
Sales de hidrobromuro de una pirazolilaminoquinazolina
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
EP2611793A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cyclochinazolinderivate und verwendungsverfahren dafür
|
WO2012030917A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
EP2611789A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Chinazolinverbindungen und anwendungsverfahren dafür
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
EP2627635A1
(de)
|
2010-10-11 |
2013-08-21 |
Axikin Pharmaceuticals, Inc. |
Salze aus arylsulfonamid-ccr3-antagonisten
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20140079686A1
(en)
|
2010-12-06 |
2014-03-20 |
Shikha P. Barman |
Methods For Treating Baldness And Promoting Hair Growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
KR101411349B1
(ko)
*
|
2010-12-24 |
2014-06-25 |
주식회사 삼양바이오팜 |
생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
|
PE20141303A1
(es)
|
2011-01-10 |
2014-10-01 |
Infinity Pharmaceuticals Inc |
Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
WO2012125475A1
(en)
|
2011-03-11 |
2012-09-20 |
Celgene Corporation |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
|
EP2691388A1
(de)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
|
JP2014509648A
(ja)
|
2011-03-28 |
2014-04-21 |
メイ プハルマ,インコーポレーテッド |
(α−置換シクロアルキルアミノ及びヘテロシクリルアミノ)ピリミジニル及び1,3,5−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
|
SG193982A1
(en)
|
2011-03-28 |
2013-11-29 |
Mei Pharma Inc |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
JP2014517076A
(ja)
|
2011-06-23 |
2014-07-17 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
新規のフルオロエルゴリン類似体
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
JP6027610B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US8785470B2
(en)
|
2011-08-29 |
2014-07-22 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2755985B1
(de)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
|
EP2755983B1
(de)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituierte carbonyloxymethylphosphoramidatverbindungen und pharmazeutische zusammensetzungen zur behandlung von virusinfektionen
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
RU2648997C2
(ru)
|
2011-10-14 |
2018-03-29 |
Эмбит Байосайенсиз Корпорейшн |
Гетероциклические соединения и способы их использования
|
WO2013056046A1
(en)
|
2011-10-14 |
2013-04-18 |
Idenix Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2859173A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
AU2012355983A1
(en)
|
2011-12-21 |
2015-01-22 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
US8916555B2
(en)
|
2012-03-16 |
2014-12-23 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
EP2852604B1
(de)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
JP6246712B2
(ja)
|
2012-07-12 |
2017-12-13 |
武田薬品工業株式会社 |
マイクロカプセル粉末の製造方法
|
NZ727295A
(en)
|
2012-08-09 |
2018-06-29 |
Celgene Corp |
Treatment of immune-related and inflammatory diseases
|
EP3524598B1
(de)
|
2012-08-09 |
2021-07-07 |
Celgene Corporation |
Eine feste form des (s)3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorids
|
US9750705B2
(en)
|
2012-08-31 |
2017-09-05 |
The Regents Of The University Of California |
Agents useful for treating obesity, diabetes and related disorders
|
AU2013312420A1
(en)
|
2012-09-07 |
2015-02-26 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
US10513534B2
(en)
|
2012-10-08 |
2019-12-24 |
Idenix Pharmaceuticals Llc |
2′-chloro nucleoside analogs for HCV infection
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
RS58023B2
(sr)
|
2012-11-01 |
2021-12-31 |
Infinity Pharmaceuticals Inc |
Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
EP2925718B1
(de)
|
2012-11-30 |
2018-08-01 |
Novomedix, LLC |
Substituierte biarylsulfonamide und verwendung davon
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
EP2943188A1
(de)
|
2013-01-11 |
2015-11-18 |
Mayo Foundation for Medical Education and Research |
Vitamine c und k zur behandlung polyzystischer erkrankungen
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
US20160113932A1
(en)
|
2013-05-30 |
2016-04-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
WO2015031613A1
(en)
|
2013-08-30 |
2015-03-05 |
Ambit Biosciences Corporation |
Biaryl acetamide compounds and methods of use thereof
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
PE20160685A1
(es)
|
2013-10-04 |
2016-07-23 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
CN104587534A
(zh)
*
|
2013-10-31 |
2015-05-06 |
先健科技(深圳)有限公司 |
可吸收铁基合金支架
|
EP3063165A1
(de)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanin-phosphoramidat-pronukleotide von 2'-methyl-2'-fluor-guanosin-nukleosid-verbindungen zur behandlung von hcv
|
EP3074399A1
(de)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichlor- und 2'-fluor-2'-chlor-nukleosidanaloga für hcv-infektion
|
CN105934438A
(zh)
|
2013-11-27 |
2016-09-07 |
艾登尼克斯药业有限公司 |
用于治疗肝癌的核苷酸
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
JP6701088B2
(ja)
|
2014-03-19 |
2020-05-27 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物
|
CA2943220C
(en)
|
2014-03-20 |
2024-01-16 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
CN106661027B
(zh)
|
2014-03-20 |
2019-12-24 |
卡佩拉医疗公司 |
苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
|
AU2015243437B2
(en)
|
2014-04-09 |
2019-08-29 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins useful for the treatment of pain
|
WO2015158823A1
(de)
|
2014-04-16 |
2015-10-22 |
Veyx-Pharma Gmbh |
Veterinärpharmazeutische zusammensetzung und deren verwendung
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
EP3444011A1
(de)
|
2014-05-12 |
2019-02-20 |
Conatus Pharmaceuticals, Inc. |
Behandlung der komplikationen von chronischer lebererkrankung mit emricasan
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
CN110526912B
(zh)
|
2014-06-19 |
2023-02-14 |
武田药品工业株式会社 |
用于激酶抑制的杂芳基化合物
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
AR101476A1
(es)
|
2014-08-07 |
2016-12-21 |
Acerta Pharma Bv |
Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
|
CN106999593A
(zh)
|
2014-09-12 |
2017-08-01 |
妥必徕疗治公司 |
用于纤维化治疗的赛尼克韦罗组合疗法
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
TN2017000157A1
(en)
|
2014-10-21 |
2018-10-19 |
Ariad Pharma Inc |
Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
|
EP3209658A1
(de)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoidderivate und verfahren zur verwendung
|
EA032473B1
(ru)
|
2014-12-23 |
2019-05-31 |
Аксикин Фармасьютикалз, Инк. |
3,5-диаминопиразоловые ингибиторы киназы
|
BR112017015510A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
|
CN107428745A
(zh)
|
2015-01-20 |
2017-12-01 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
US10815264B2
(en)
|
2015-05-27 |
2020-10-27 |
Southern Research Institute |
Nucleotides for the treatment of cancer
|
EP3302354B1
(de)
|
2015-06-03 |
2023-10-04 |
i2o Therapeutics, Inc. |
Systeme zum einsetzen eines implantats
|
WO2016210180A2
(en)
|
2015-06-23 |
2016-12-29 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
RS59158B9
(sr)
|
2015-08-17 |
2020-09-30 |
Kura Oncology Inc |
Postupci lečenja pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
|
US10112953B2
(en)
|
2015-09-30 |
2018-10-30 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
PT3875459T
(pt)
|
2015-10-30 |
2024-02-21 |
Neurocrine Biosciences Inc |
Ditosilato de valbenazina e polimorfos dos mesmos
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
CN108925135A
(zh)
|
2015-12-23 |
2018-11-30 |
纽罗克里生物科学有限公司 |
制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
|
CA3010286A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
ES2959267T3
(es)
|
2016-01-08 |
2024-02-22 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
|
EP3399980A4
(de)
|
2016-01-08 |
2019-09-04 |
Celgene Corporation |
Verfahren zur behandlung von krebs und verwendung von biomarkern als prädiktor klinischer empfindlichkeit gegenüber therapien
|
PT3399978T
(pt)
|
2016-01-08 |
2020-11-19 |
Celgene Corp |
Compostos antiproliferativos e as suas composições farmacêuticas e utilizações
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
JP2019513707A
(ja)
|
2016-04-11 |
2019-05-30 |
クレキシオ バイオサイエンシーズ エルティーディー. |
重水素化ケタミン誘導体
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
CA3022395A1
(en)
|
2016-04-29 |
2017-11-02 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
BR112018073511A2
(pt)
|
2016-05-16 |
2019-03-26 |
Intarcia Therapeutics, Inc. |
polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP7071981B2
(ja)
|
2016-09-07 |
2022-05-19 |
エフジーエイチ バイオテック,インコーポレーテッド |
疾患の治療のための二置換ピラゾール化合物
|
MA46285A
(fr)
|
2016-09-19 |
2019-07-31 |
Mei Pharma Inc |
Polythérapie
|
AR110031A1
(es)
|
2016-11-03 |
2019-02-13 |
Kura Oncology Inc |
Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa
|
AU2017356926B2
(en)
|
2016-11-09 |
2024-01-04 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
EP3548027A1
(de)
|
2016-12-02 |
2019-10-09 |
Neurocrine Biosciences, Inc. |
Verwendung von valbenazin zur behandlung von schizophrenie oder schizoaffektiver störung
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
MY195934A
(en)
|
2017-01-27 |
2023-02-27 |
Neurocrine Biosciences Inc |
Methods for the Administration of Certain VMAT2 Inhibitors
|
TWI738314B
(zh)
|
2017-02-21 |
2021-09-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
WO2018175324A1
(en)
|
2017-03-20 |
2018-09-27 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
CN110831945B
(zh)
|
2017-03-29 |
2023-08-08 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
JP2020515611A
(ja)
|
2017-03-29 |
2020-05-28 |
サイトワン セラピューティクス, インコーポレイテッド |
疼痛の処置のための11,13−修飾サキシトキシン
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
WO2018213807A1
(en)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Fused heteroaromatic-aniline compounds for treatment of dermal disorders
|
MX2019013561A
(es)
|
2017-05-19 |
2022-02-09 |
Nflection Therapeutics Inc |
Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
|
BR112019025420A2
(pt)
|
2017-06-01 |
2020-06-16 |
Xoc Pharmaceuticals, Inc. |
Compostos policíclicos e usos destes
|
JP7325400B2
(ja)
|
2017-08-07 |
2023-08-14 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
IL273300B1
(en)
|
2017-09-21 |
2024-02-01 |
Neurocrine Biosciences Inc |
High dose valbenazine formulation and related preparations, methods and kits
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
特定のvmat2インヒビターを投与するための方法
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
CA3087856A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
BR112020024018A2
(pt)
|
2018-06-14 |
2021-02-23 |
Neurocrine Biosciences Inc. |
compostos inibidores de vmat2, composições e métodos relacionados a eles
|
EP3814327A1
(de)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorphenoxy)pentansäure-derivate und verwandte verbindungen als caspase-inhibitoren zur behandlung kardiovaskulärer erkrankungen
|
JP2021528481A
(ja)
|
2018-08-15 |
2021-10-21 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
特定のvmat2阻害剤を投与するための方法
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US20220002396A1
(en)
|
2018-11-01 |
2022-01-06 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3883553A4
(de)
|
2018-11-20 |
2022-11-02 |
NFlection Therapeutics, Inc. |
Aryl-anilin- und heteroaryl-anilinverbindungen zur behandlung von hautkrebs
|
US20220144819A1
(en)
|
2018-11-20 |
2022-05-12 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
WO2020106306A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
CA3120336A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
JP2022514654A
(ja)
|
2018-12-21 |
2022-02-14 |
クラ オンコロジー, インコーポレイテッド |
扁平上皮癌のための治療法
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
EP3921038A1
(de)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020181165A1
(en)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Caspase inhibitors and methods of use thereof
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TW202043487A
(zh)
|
2019-03-29 |
2020-12-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
US20220274922A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
BR112022000993A2
(pt)
|
2019-07-26 |
2022-06-07 |
Espervita Therapeutics Inc |
Ácidos mono- e dicarboxílicos de hidrocarboneto de cadeia longa funcionalizados úteis para a prevenção ou tratamento de doença
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
BR112022004802A2
(pt)
|
2019-09-16 |
2022-08-23 |
Dice Alpha Inc |
Moduladores de il-17a e usos dos mesmos
|
WO2021059023A1
(en)
|
2019-09-26 |
2021-04-01 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
CA3151626A1
(en)
|
2019-10-01 |
2021-04-08 |
Molecular Skin Therapeutics, Inc. |
Benzoxazinone compounds as klk5/7 dual inhibitors
|
CA3179635A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
JP2023537632A
(ja)
|
2020-08-14 |
2023-09-04 |
サイトワン セラピューティクス インコーポレイテッド |
疼痛の処置のためのNaV1.7の非水和ケトン阻害剤
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
EP4304716A1
(de)
|
2021-03-10 |
2024-01-17 |
Dice Molecules Sv, Inc. |
Alpha-v-beta-6- und alpha-v-beta-1-integrinhemmer und verwendungen davon
|
EP4326721A1
(de)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
|
EP4347568A1
(de)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryldiamid-ire1/xbp1s-aktivatoren
|
WO2023102378A1
(en)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023192817A1
(en)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|